Lv5
950 积分 2021-03-06 加入
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer
10天前
已完结
Emerging Anti-Cancer and Repurposed Therapies for Overcoming Multidrug Resistance in Lung Cancer
16天前
已完结
Ivonescimab delays disease progression
16天前
已完结
Metastatic Lymph Node Burden and Invasive Tumour Features Inform First Recurrence Patterns After Curative-Intent Resection for Intrahepatic Cholangiocarcinoma
16天前
已完结
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
1个月前
已完结
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
1个月前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
1个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1个月前
已完结
CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis
1个月前
已关闭
CT Radiomics–based Machine Learning to Identify Intratumoral Fibrosis and Underlying Angiogenesis in Hepatocellular Carcinoma
1个月前
已完结
皖公网安备34019202002308
